

## C0. Introduction

---

### C0.1

---

#### **(C0.1) Give a general description and introduction to your organization.**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Our commitment at Pfizer is to ensure that people have the opportunity to lead healthier lives. While it starts with discovery and development of medicines, it is only made a reality when individuals everywhere have access to quality medicines and healthcare. Together, with partners around the world, progress has been made in advancing longer and healthier lives. Signature corporate responsibility programs aim to eliminate trachoma, broaden access to contraceptives, reduce pneumococcal disease in the world's poorest countries, and help uninsured and underinsured patients in our communities get access to the medicines they need. We have an important role to play in addressing the UN Sustainable Development Goals for 2030 and know that the public and private sectors must work together to improve healthcare quality and access around the world.

Pfizer is committed to Corporate Responsibility. We believe improving our impact on society strengthens our company, reinforces our license to operate, and fulfills our business purpose. In partnership with public and private institutions, foundations, non-government organizations and governments we are working to meet the health needs of the underserved while investing in the health of our communities and in the health of our business.

Pfizer is working toward a sustainable future. By striving for environmental sustainability across all aspects of our organization, we aim to add value to society and our business by doing our part in mitigating climate change and its impact, looking for opportunities to minimize the environmental impact of our products and managing water resources. Our goals focus on three areas that are important to our business: reducing carbon emissions, water withdrawal and waste disposal.

Disclosure Notice: The information contained in this response is as of Aug 28, 2019. Pfizer assumes no obligation to update forward-looking statements contained in this response as the result of new information or future events or developments. This response contains forward-looking information about potential impacts of climate change to Pfizer, including regulatory, physical and business risks and opportunities, and information related to climate change strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing, or implementation of new regulations; projected financial impact and management cost; and projected performance on climate change related goals. Pfizer's past performance in attaining reductions in greenhouse gas emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer's Form 10-K for the fiscal year ended December 31, 2018, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).

### C0.2

---

**(C0.2) State the start and end date of the year for which you are reporting data.**

	Start date	End date	Indicate if you are providing emissions data for past reporting years	Select the number of past reporting years you will be providing emissions data for
Row 1	January 1 2018	December 31 2018	Yes	1 year

**C0.3**

---

**(C0.3) Select the countries/regions for which you will be supplying data.**

- Algeria
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- Colombia
- Croatia
- Denmark
- Ecuador
- Egypt
- Finland
- France
- Germany
- Greece
- India
- Indonesia
- Ireland
- Italy
- Japan
- Lebanon
- Mexico
- Morocco
- Netherlands
- Pakistan
- Portugal
- Puerto Rico
- Republic of Korea
- Russian Federation
- Saudi Arabia
- Senegal
- Singapore
- South Africa
- Spain
- Sweden
- Switzerland
- Taiwan, Greater China
- Tunisia
- Turkey
- United Kingdom of Great Britain and Northern Ireland
- United States of America
- Venezuela (Bolivarian Republic of)

**C0.4**

---

**(C0.4) Select the currency used for all financial information disclosed throughout your response.**

USD

**C0.5**

**(C0.5) Select the option that describes the reporting boundary for which climate-related impacts on your business are being reported. Note that this option should align with your consolidation approach to your Scope 1 and Scope 2 greenhouse gas inventory.**

Operational control

**C1. Governance**

**C1.1**

**(C1.1) Is there board-level oversight of climate-related issues within your organization?**

Yes

**C1.1a**

**(C1.1a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for climate-related issues.**

Position of individual(s)	Please explain
President	Pfizer's Global EHS function runs an Operational Risk Review (ORR) program that monitors risk associated with EHS matters (including climate change). Risk assessments, rankings and key risk management activities from the ORR process are communicated to senior leadership of Pfizer's Global Supply Quality & Compliance Committee (PGS QCC) and the PGS Leadership Team.
Chief Executive Officer (CEO)	The PGS QCC periodically reports key risks to: (i) the Executive Compliance Committee (ECC), composed of Pfizer's Executive Leadership Team (ELT) and Chief Internal Auditor and chaired by the Chief Executive Officer, and (ii) the Regulatory & Compliance Committee (RCC) of the Board of Directors.
Board-level committee	The PGS QCC periodically reports key risks to: (i) the Executive Compliance Committee (ECC), composed of Pfizer's Executive Leadership Team (ELT) and Chief Internal Auditor and chaired by the Chief Executive Officer, and (ii) the Regulatory & Compliance Committee (RCC) of the Board of Directors.
Board-level committee	The Internal Audit function is responsible for conducting periodic audits of EHS areas/processes and reporting those results to the Audit Committee. In addition, Pfizer's Enterprise Risk Management (ERM) program provides a framework for risk identification and management of significant risks, which could potentially include risks related to climate change. Each risk is assigned to a member or members, as appropriate, of our ELT. ERM is conducted at the direction of Legal and the Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program. Further, as reflected in its charter, one of the responsibilities of the Corporate Governance Committee is to maintain an informed status on Company issues related to corporate social responsibility, sustainability, philanthropy, and the Company's participation and visibility as a global corporate citizen.

**C1.1b**

**(C1.1b) Provide further details on the board’s oversight of climate-related issues.**

Frequency with which climate-related issues are a scheduled agenda item	Governance mechanisms into which climate-related issues are integrated	Please explain
Sporadic - as important matters arise	Reviewing and guiding risk management policies Setting performance objectives	The Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer’s Enterprise Risk Management program. The ERM program provides a framework for risk identification and management, which could include risks related to climate change. The CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for approving environmental sustainability-related public goals.

**C1.2**

**(C1.2) Provide the highest management-level position(s) or committee(s) with responsibility for climate-related issues.**

Name of the position(s) and/or committee(s)	Responsibility	Frequency of reporting to the board on climate-related issues
Other C-Suite Officer, please specify (CFO & EVP, Global Supply and Business Operations)	Both assessing and managing climate-related risks and opportunities	Annually
President	Both assessing and managing climate-related risks and opportunities	Annually
Sustainability committee	Other, please specify (Developing next generation goals)	Not reported to the board

**C1.2a**

**(C1.2a) Describe where in the organizational structure this/these position(s) and/or committees lie, what their associated responsibilities are, and how climate-related issues are monitored (do not include the names of individuals).**

Product manufacturing at our internal network of sites, managed by Pfizer’s Global Supply division (PGS), accounts for 70% of the company’s energy consumption and GHG emissions. The CFO & EVP, Global Supply and Business Operations, leads Pfizer’s manufacturing and supply division and serves as the executive “risk owner” for the company’s business continuity risk and key elements of climate change risk. The President, PGS has operational control over PGS operations and strategy, including OPEX and CAPEX investment in emission reduction projects. Environmental sustainability has been integrated into the overarching PGS strategy and GHG emissions reduction is monitored as a key performance indicator. Performance against this goal is included in a monthly dashboard reviewed by the CFO & EVP.

In 2018, Pfizer’s Environmental Sustainability 2025 Strategy Team was established to lead the development of the next generation environmental sustainability strategy and public goals. The team is comprised of members from EHS, Global Engineering, Legal, Compliance, Procurement, External Supply, R&D, and Strategy & Innovation. The team’s recommendations will be socialized with Pfizer leadership and ultimately approved by the CEO.

**C1.3**

**(C1.3) Do you provide incentives for the management of climate-related issues, including the attainment of targets?**

Yes



**(C1.3a) Provide further details on the incentives provided for the management of climate-related issues (do not include the names of individuals).**

**Who is entitled to benefit from these incentives?**

Other C-Suite Officer

**Types of incentives**

Monetary reward

**Activity incentivized**

Energy reduction project

**Comment**

Energy savings is a component of overall savings target included in goals against which monetary awards were determined for executive leadership.

---

**Who is entitled to benefit from these incentives?**

Business unit manager

**Types of incentives**

Monetary reward

**Activity incentivized**

Emissions reduction target

**Comment**

Operating unit leaders - target for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal), were included in goals against which monetary awards were determined.

---

**Who is entitled to benefit from these incentives?**

Energy manager

**Types of incentives**

Monetary reward

**Activity incentivized**

Emissions reduction target

**Comment**

Site-specific targets for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal), are included in goals against which monetary awards were determined.

---

**Who is entitled to benefit from these incentives?**

Other, please specify (Manufacturing Site Leaders)

**Types of incentives**

Monetary reward

**Activity incentivized**

Emissions reduction target

**Comment**

Site-specific target for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal) are included in goals against which monetary awards were determined.

---

**Who is entitled to benefit from these incentives?**

All employees

**Types of incentives**

Recognition (non-monetary)

**Activity incentivized**

Emissions reduction project

**Comment**

Colleagues and teams are recognized under the global "Safety and Sustainability STAR Awards Program" for outstanding efforts and projects contributing to and advancing initiatives for Pfizer's Green Journey.

---

## C2. Risks and opportunities

---

### C2.1

---

**(C2.1) Describe what your organization considers to be short-, medium- and long-term horizons.**

	From (years)	To (years)	Comment
Short-term	0	5	
Medium-term	5	10	
Long-term	10	30	

### C2.2

---

**(C2.2) Select the option that best describes how your organization's processes for identifying, assessing, and managing climate-related issues are integrated into your overall risk management.**

Integrated into multi-disciplinary company-wide risk identification, assessment, and management processes

### C2.2a

---

**(C2.2a) Select the options that best describe your organization's frequency and time horizon for identifying and assessing climate-related risks.**

	Frequency of monitoring	How far into the future are risks considered?	Comment
Row 1	Six-monthly or more frequently	>6 years	Pfizer performs an annual detailed assessment of climate change risk and monitors it quarterly as part of our Operational Risk Review process. The scope of Pfizer's risk management processes is enterprise-wide and encompasses Pfizer locations and business operations under operational control (including manufacturing, research and development, commercial operations, and logistic centers) as well as risk from outsourced manufacturing and research worldwide. These annual assessments focus on short- to medium-term risk.

### C2.2b

---

**(C2.2b) Provide further details on your organization's process(es) for identifying and assessing climate-related risks.**

*i. How climate-related risks are identified and assessed at a company level*

Pfizer assesses climate change risk as part of our Enterprise Level EHS & Business Continuity Risk Management Process. Under this process, we conduct Operational Risk Evaluations (OREs) which are structured evaluations of risks with the potential to have substantive impact to Pfizer, which we define as any impact that could adversely impact the company's business or financial condition or disrupt, delay or inhibit the supply of medically-necessary products to patients. The process further evaluates the controls in place to manage or mitigate the risk and a determination of the adequacy of the control of risk. Climate change risk is evaluated by a team that includes relevant program leaders and subject matter experts from EHS, Global Engineering and Business Resilience, Legal, and Audit. Evaluation results are reported to Pfizer's Executive Compliance Committee. To the extent highly significant matters from the report to the ECC are identified they would be reported to the Regulatory and Compliance Committee and/or the Audit Committee of the Board.

*ii. How climate –related risks are identified and assessed at an asset level*

Pfizer has a program for reviewing our vulnerability to potential weather-related risks at our facilities and in our supply chain; these assessments are updated periodically. At the asset level, assessment of risks is managed through Pfizer's Insurance and Business Continuity teams both at the enterprise and local level. Members from those teams participate in the risk review process that addresses Business Continuity/Resiliency and provide input on the potential impact of physical risks that may be related to climate change (e.g. severe weather events, flooding). Energy assessments of our facilities are an integral layer of protection in this risk management process and include a detailed evaluation, identification and prioritization of energy use reduction measures; confirmation of data; and interviews with site colleagues.

*iii. The process Pfizer has in place to assess the potential size and scope of identified risks*

The annual Climate Change ORE is designed to assess potential risk to Pfizer across four risk factors, including: External/Reputational, Physical, Regulatory/Legal, and Market & Technology Risks. Individual risks across each of the four risk factors are evaluated and rated based on the severity, vulnerability, and risk to Pfizer with the goal to ensure that sufficient controls are in place to effectively mitigate Climate Change risks and prevent material impact to Pfizer.

*iv. The process by which your organization determines the relative significance of climate related risks in relation to other risk*

Using the ORE, we assess risk factors based on the severity and vulnerability. We define high severity as loss of the capability to produce products as the result of extensive damage, shut-down, or substantial loss of plant. We define high vulnerability as controls that are not as robust as would be reasonably expected across multiple layers, suggesting increased potential for significant failure of risk control. The higher the severity and the vulnerability, the higher we define overall risk. Based on the risk scores, we prioritize action. Of all the TCFD categories of climate risks, we have determined the most significant potential threat related to our operations is physical risk.

*v. The definition of risk terminologies used (or reference to existing risk classification framework)*

The risk evaluation for each scenario is listed in a risk register as a product of scores assigned to the potential severity of an impact (assuming no controls) and to an assessment of the controls in place, with reference to a suitable authoritative assessment methodology (e.g., based on international standards and industry best practice).

*vi. How Pfizer defines substantive financial or strategic impact on our business*

For the purposes of this response, Pfizer defines "substantive" risk as any impact that could adversely impact the company's business or financial condition or disrupt, delay or inhibit the supply of medically-necessary products to patients. CDP's phrasing of "substantive" and our response to questions presenting "substantive" risks should not be considered to relate to matters or facts that could be deemed "material" to a reasonable investor as referred to under U.S. securities laws or similar requirements of other jurisdictions. Investors should refer to disclosures in our Annual Report on Form 10-K and in our other filings with the US Securities and Exchange Commission, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of "material" matters.

## C2.2c

---

**(C2.2c) Which of the following risk types are considered in your organization's climate-related risk assessments?**

	Relevance & inclusion	Please explain
Current regulation	Relevant, always included	Pfizer assesses the impacts of existing regulatory requirements and voluntary agreements as part of our risk review. We look at current regulation pertaining to voluntary agreements, existing or emerging market-based regulatory requirements to lower emissions, renewable energy standards, and other environmental legislation/regulations. To manage and reduce risk, in our most recent review we assessed the effectiveness of our internal environmental impact reduction requirements and our voluntary GHG reduction goals to ensure conformance in regions which have already implemented cap-and-trade requirements. Pfizer is acting independently to help achieve the initial goals set through the Paris Agreement. An example of this is our monitoring process for existing cap-and-trade programs that apply to our operations in Ireland and Italy, which are subject to the EU ETS.
Emerging regulation	Relevant, always included	Pfizer assesses the impacts of emerging regulatory requirements and voluntary agreements as part of our risk review, such as the potential impact of the implementation of cap-and-trade programs in China on our operations. Beyond just tracking emerging regulation, a team has been formed to get ahead of requirements and outline a framework for an internal carbon price which will help us be more efficient and reduce emissions in advance of regulations. The team is proposing a shadow pricing scheme and with further internal stakeholder input will finalize the process to integrate the price.
Technology	Relevant, always included	Pfizer assesses the impacts of changing technology on its operations as part of the risk review. Our most recent review included an assessment of the impact of the phase-out of high Global Warming Potential refrigerants on our operations. As we look forward, we are also monitoring the benefits of new technologies to increase the efficiency of our operations to enable maintenance of competitiveness in the event of energy cost increases. Beyond our programs to reward greenhouse gas reduction at all employee levels in the organization, we also challenge our operational teams to identify opportunities for technological improvements. For example, a team at our Sholingnallur, India R&D site recently developed an improved process for the manufacture of an antibacterial product that improved yield and reduced the product's E-factor by half.
Legal	Not relevant, included	Pfizer has not received any climate-related litigation claims but does consider the potential for such claims as part of the risk review. Given the relatively limited quantity of climate-related regulation covering our operations, as well as, our proactive position where voluntary GHG reduction targets and goals position us to meet future external regulatory/legal requirements, our legal risks are limited.
Market	Relevant, always included	Climate change could have a ripple effect on the availability of natural resources or shifting of disease patterns. By 2050, climate change is projected to cause 250,000 additional deaths per year from malnutrition, malaria, diarrhoea and heat stress. With a vast portfolio and expansive geographic reach, we have been able to consistently meet the diverse needs of, and provide significant value and impact to, patients and health care professionals around the world in an innovative, socially responsible and commercially viable manner. To integrate this risk, Pfizer continues to monitor published reports from the Center for Disease Control (CDC) and World Health Organization on projections of health impacts.
Reputation	Relevant, always included	Our risk review considers potential risk to reputation if we do not meet stakeholder expectations on voluntary disclosures, policy position, and alignment on climate change policy with trade associations. We also have extensive reporting on our climate action strategies through our website, integrated report, and the annual CDP response. Through these formats, we communicate with our stakeholders about the actions that we are taking to manage climate change risks. Several of our sites have been recognized by external stakeholders for their environmental efforts. For example, our Vega Baja, Puerto Rico site's commitment to environmental sustainability was recently recognized by the Puerto Rico Manufacturer's Association. The site received the organization's Environmental Sustainability Gold Award for their water management and energy reduction efforts in 2018/2019.
Acute physical	Relevant, always included	Our risk review process addresses the potential impacts of acute and chronic physical risks on our operations and those of our direct material suppliers. In 2018 we initiated a detailed risk review process to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilized available models to assess risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and tsunamis. To date we have completed these assessments for all our internal manufacturing facilities and for over 5,000 of our material suppliers. We are currently working to develop risk reduction plans for areas of high risk, such as at our Puerto Rico facilities where we experienced detrimental impacts as a result of Hurricane Maria in 2017.
Chronic physical	Relevant, always included	Our Business Resilience risk review process addresses the potential impacts of acute and chronic physical risks on our operations and those of our direct material suppliers. In 2018 we initiated a detailed risk review process to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilized available models to assess risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and tsunamis. To date we have completed these assessments for all our internal manufacturing facilities and for over 5,000 of our material suppliers. One example of chronic risk considered as part of our review is the impact of flooding on our Taiwan commercial office where as a result flood gates were installed and have prevented major issues during flood conditions. We also completed water supply studies in 2018 for one of our manufacturing sites in India and continue to monitor water availability and the impacts of seasonal water shortages for all our Indian sites.
Upstream	Relevant, always included	Pfizer assesses risk associated with direct material suppliers and contract manufacturers as part of our Business Continuity/Business Resilience program. We recently completed assessments of acute and chronic physical risk for over 5,000 of our material suppliers and are in the process of completing assessments for our contract manufacturers (CMOs). For our CMO suppliers that are responsible for 100 million in revenue or produce Medically Necessary Products, we support the development of controls and drive improvement around engagement and the closure of outstanding risks.
Downstream	Relevant, always included	Over the past five years Pfizer has been conducting life cycle analyses for the active pharmaceutical ingredients (API) in our portfolio, including both those currently being developed and those that are commercially available. The API component of small molecule pharmaceutical products accounts for an average of 70% of the total carbon footprint. We have fully characterized the carbon footprint for several of our commercial products and are currently identifying next steps to fully characterize additional products.

**C2.2d**

## **(C2.2d) Describe your process(es) for managing climate-related risks and opportunities.**

### *Managing climate related risks*

Pfizer has integrated climate change into its risk management process which includes a periodic review of risk that could be material to the company (SEC 10-K reporting) and an evaluation of facility and supply chain activities (performed through our insurance and business continuity/EHS functions and Operational Risk Review process) to ensure climate change risks are understood and if appropriate, acted on.

Assessment of risks is managed through Pfizer's Insurance and Business Continuity teams both at the enterprise and local level. Members from those teams participate in the risk review process that addresses Business Continuity/Resiliency and provide input on the potential impact of physical risks that may be related to climate change (e.g. severe weather events, flooding). Energy assessments of our facilities are an integral layer of protection in this risk management process and include a detailed evaluation, identification and prioritization of energy use reduction measures; confirmation of data; and interviews with site colleagues. For example, an ongoing program of energy assessments performed at our Grange Castle facility as part of their ISO50001 certified energy management program has identified multiple projects to continually reduce the site's energy consumption. Twelve significant projects were implemented in 2018, reducing GHG emissions by 1,400 mtCO<sub>2</sub>e, representing more than 3% of the site's footprint.

### *Managing climate related opportunities*

Pfizer takes a two-tiered approach to integrating opportunities into our business strategy. The first opportunity seized upon changing customer demands. Pfizer reports on our environmental sustainability achievements in tender requests (e.g., French public hospital associations), retailer surveys (i.e., Walmart) and providing information on the Pfizer website (e.g., Lipitor packaging and process improvements). Increasingly customers are incorporating the environmental criteria into their procurement programs. The projected revenue from customers requesting this information is more than \$100M for pharmaceutical products. The environmental criteria accounts for 1% to 10% of the weighting in the purchasing decision; however, it is indicative of an increased focus on products that are produced responsibly and the need for Pfizer to continue to improve the environmental efficiency of our operations and our products.

Our 2025 Environmental Sustainability Strategy Team is currently working to identify opportunities to further reduce Pfizer's GHG footprint and to propose our next generation of environmental sustainability goals for leadership endorsement.

The second approach to evaluating opportunities is to assess emerging disease trends and the potential increase in demand for Pfizer products to treat these diseases. Pfizer has reviewed published disease trend information associated with climate related diseases. The information will be continually reviewed to identify potential opportunities for Pfizer to provide life-saving medicines from our portfolio.

## **C2.3**

---

### **(C2.3) Have you identified any inherent climate-related risks with the potential to have a substantive financial or strategic impact on your business?**

Yes

## **C2.3a**

---

### **(C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your business.**

**Identifier**

Risk 1

**Where in the value chain does the risk driver occur?**

Direct operations

**Risk type**

Transition risk

**Primary climate-related risk driver**

Policy and legal: Increased pricing of GHG emissions

**Type of financial impact**

Increased operating costs (e.g., higher compliance costs, increased insurance premiums)

**Company- specific description**

Following the Paris Agreement, more than 40 nations and over 20 other jurisdictions have begun putting a price on carbon emissions. Although not financially substantive, the issue does have strategic impact. Singapore will levy a \$5/ton tax in 2020 on facilities exceeding 25,000 tons of GHG emissions in 2019. This will increase the site's energy spend by approximately 3%. The implementation of a US tax such as that proposed by Americans for Carbon Dividends or the Climate Leadership Council could increase Pfizer's operational cost (direct costs associated with internal sites and fleet and indirect costs associated with charge-back from external suppliers) by ~25%. Other regions where Pfizer operates also plan to implement carbon pricing. To mitigate the impact from carbon fees, Pfizer continues efforts to meet our Science Based Targets and 2020 public reduction goals. As part of the 2025 strategy development process we are proposing the establishment of an internal carbon shadow price initiative.

**Time horizon**

Medium-term

**Likelihood**

Very likely

**Magnitude of impact**

Medium-low

**Are you able to provide a potential financial impact figure?**

Yes, an estimated range

**Potential financial impact figure (currency)**

&lt;Not Applicable&gt;

**Potential financial impact figure – minimum (currency)**

160000

**Potential financial impact figure – maximum (currency)**

4300000

**Explanation of financial impact figure**

Estimated costs associated with the implementation of new carbon taxes and/or cap-and-trade schemes in regions where we operate, including the United States, Singapore and China.

**Management method**

Pfizer evaluates climate change risk as part of its operating risk review process. Regulatory risks arising from current and/or expected local, state, regional, national or global governmental regulations or legislation related to climate change are assessed on a periodic basis. In addition, Pfizer managed risk through effective GHG reduction goals and internal energy efficiency targets to reduce potential costs associated with purchase or generation of energy; Pfizer's Climate Change Position Statement (used to evaluate and position relative to emerging legislation/regulation); an internal EHS regulatory tracking and emerging issues alert process; Pfizer's internal audit program to ensure compliance with regulatory requirements and site EHS colleagues to manage implementation.

**Cost of management**

10000000

**Comment**

Integrated into staff costs and membership dues which are estimated to be <0.05% of total 2018 revenue (\$53.6bn) on an annual basis. Energy efficiency project OPEX and CAPEX costs for 2018 were \$19MM.

---

**Identifier**

Risk 2

**Where in the value chain does the risk driver occur?**

Direct operations

**Risk type**

Physical risk

**Primary climate-related risk driver**

Acute: Increased severity of extreme weather events such as cyclones and floods

**Type of financial impact**

Reduced revenue from decreased production capacity (e.g., transport difficulties, supply chain interruptions)

**Company- specific description**

Climate change presents risks to our operations, including the potential for additional regulatory requirements and associated costs, and the potential for more frequent and severe weather events and water availability challenges that may impact our facilities and those of our suppliers. For example, in 2017, our manufacturing and commercial operations in Puerto Rico were impacted by hurricanes. To evaluate the ongoing potential from severe weather events, we initiated a detailed risk review process to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilized available models to assess short, medium and long-term risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and tsunamis. To date we have completed these assessments for all our internal manufacturing facilities and for over 5,000 of our material suppliers. We are currently working to develop risk reduction plans for areas of identified risk. We cannot provide assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future; however, we have a program for reviewing our vulnerability to potential weather-related risks and we update our assessments periodically. To date, we have concluded that, because of our facility locations, our existing distribution networks and our controls, we do not anticipate that these risks will have a material impact on Pfizer in the near term.

**Time horizon**

Medium-term

**Likelihood**

Unlikely

**Magnitude of impact**

Medium-low

**Are you able to provide a potential financial impact figure?**

Yes, a single figure estimate

**Potential financial impact figure (currency)**

100000000

**Potential financial impact figure – minimum (currency)**

<Not Applicable>

**Potential financial impact figure – maximum (currency)**

<Not Applicable>

**Explanation of financial impact figure**

The potential financial loss we could reasonably expect as a result of property damage and business interruption at any of Pfizer's facilities in Puerto Rico.

**Management method**

Pfizer's Business Continuity program identifies potential supply chain vulnerabilities and establishes contingency plans to maintain supply. For example, alternative sourcing options and holding multiple weeks of buffer inventory (depending on product).

**Cost of management**

2000000

**Comment**

Pfizer maintains resources for assessing and putting in place business continuity arrangements. Supply chain and business continuity professionals are retained as staff and consultants to ensure that Pfizer's supply chain is sufficiently resilient. Integrated into existing budgets; estimated direct staff costs of \$2MM.

---

**Identifier**

Risk 3

**Where in the value chain does the risk driver occur?**

Direct operations

**Risk type**

Transition risk

**Primary climate-related risk driver**

Reputation: Increased stakeholder concern or negative stakeholder feedback

**Type of financial impact**

Reduced revenue from decreased demand for goods/services

**Company- specific description**

Although not financially substantive, Pfizer's participation in various industry associations does have a potential strategic impact because certain stakeholders disagree with the environmental positions of these organizations. We are committed to voicing our concerns as appropriate through representatives on the boards and committees of these groups. Pfizer is one of a number of "like-minded" companies that established the Climate Solutions Working Group (CSWG), an informal group of U.S. Chamber of Commerce companies, in 2017 for the purpose of advancing business interests in climate change solutions and clean energy markets. The CSWG worked with the U.S Chamber of Commerce to influence the Chamber's recently released climate policy statement. The statement, while a document of compromise, makes clear that climate change is a serious issue, a risk to businesses, and that inaction is not an option.

**Time horizon**

Medium-term

**Likelihood**

About as likely as not

**Magnitude of impact**

Low

**Are you able to provide a potential financial impact figure?**

Yes, an estimated range

**Potential financial impact figure (currency)**

<Not Applicable>

**Potential financial impact figure – minimum (currency)**

500000

**Potential financial impact figure – maximum (currency)**

5000000

**Explanation of financial impact figure**

It can be difficult to directly correlate financial implications resulting from potentially negative impact to reputation. The range of \$500,000 - \$5M includes engagement time with stakeholders, the shareholder proposal process, legal evaluation, SEC reporting and inclusion of a proposal within the annual proxy statement.

**Management method**

In conjunction with Corporate Responsibility, Investor Relations, and the Corporate Secretary, Pfizer conducts stakeholder engagement sessions annually with impact and mainstream investors. These sessions provide useful insights into concerns regarding our involvement in various organizations and the effectiveness of our efforts to influence these organizations.

**Cost of management**

10000

**Comment**

There are minimal costs associated with managing this risk. Pfizer leverages its internal social networking tools and SharePoint sites to distribute timely information on market developments and changing consumer behaviors. There are only minor costs associated with monitoring these developments, such as the costs of organizational memberships, conference fees, and subscriptions to trade newsletters.

---

**C2.4****(C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?**

Yes

**(C2.4a) Provide details of opportunities identified with the potential to have a substantive financial or strategic impact on your business.**

**Identifier**

Opp1

**Where in the value chain does the opportunity occur?**

Customer

**Opportunity type**

Products and services

**Primary climate-related opportunity driver**

Development of new products or services through R&D and innovation

**Type of financial impact**

Increased revenue through new solutions to adaptation needs (e.g., insurance risk transfer products and services)

**Company-specific description**

By 2050, climate change is projected to cause 250,000 additional deaths per year from malnutrition, malaria, diarrhoea and heat stress. With a vast portfolio and expansive geographic reach, we have been able to consistently meet the diverse needs of, and provide significant value and impact to, patients and health care professionals around the world in an innovative, socially responsible and commercially viable manner. We have large, diverse portfolios of anti-infective therapies with more than 80 life-saving medicines.

**Time horizon**

Medium-term

**Likelihood**

About as likely as not

**Magnitude of impact**

Low

**Are you able to provide a potential financial impact figure?**

No, we do not have this figure

**Potential financial impact figure (currency)**

<Not Applicable>

**Potential financial impact figure – minimum (currency)**

<Not Applicable>

**Potential financial impact figure – maximum (currency)**

<Not Applicable>

**Explanation of financial impact figure**

The potential financial implications of this opportunity are unknown; however, there could be an increased demand for products related to diseases impacted by climate change.

**Strategy to realize opportunity**

Our overall Corporate Responsibility Program is well poised to address the potential opportunities climate change may present with respect to health. Pfizer combines traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public-health systems to facilitate access to healthcare for under-served communities around the world. Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three part approach, including product donations, cash grants, and other access solutions. Our work makes the best use of Pfizer's resources—our people, products, and funding—to address complex healthcare challenges. These efforts would not be possible without our partnerships with non-profit organizations, governments, and foundations. Our portfolio of programs range from donating Pfizer medicines and volunteering valuable employee skills to providing grants and investments that support social entrepreneurs and enterprises, fostering local innovation and improving healthcare delivery and access.

**Cost to realize opportunity**

0

**Comment**

The costs associated with these actions are not easily determined at this time.

---

**Identifier**

Opp2

**Where in the value chain does the opportunity occur?**

Direct operations

**Opportunity type**

Resource efficiency

**Primary climate-related opportunity driver**

Use of more efficient production and distribution processes

**Type of financial impact**

Reduced operating costs (e.g., through efficiency gains and cost reductions)

**Company-specific description**

Pfizer continually drives the improvement of efficiency at our operations. At the corporate level, through more than 4,000 projects, we have reduced our GHG emissions by ~60% since 2000 and are on our way to achieve our 2020 goal which will keep us on the trajectory to reach a 75% reduction by 2050 (our current Science Based Target). We are establishing our next generation climate action strategy and expect to continue to deliver reductions. At the product level, green chemistry (the design of chemical products and processes that reduce or eliminate the use and generation of hazardous substances) delivers process efficiencies. Our new two-step process for the anti-fungal drug Voriconazole replaced a six-step process. The new process requires less equipment, shrinking the overall carbon footprint by ~35% and lowered the cost of making the drug by 30%.

**Time horizon**

Current

**Likelihood**

Virtually certain

**Magnitude of impact**

Medium-low

**Are you able to provide a potential financial impact figure?**

Yes, an estimated range

**Potential financial impact figure (currency)**

&lt;Not Applicable&gt;

**Potential financial impact figure – minimum (currency)**

3000000

**Potential financial impact figure – maximum (currency)**

5000000

**Explanation of financial impact figure**

Pfizer achieves an annual savings of \$3-5MM per year through the implementation of emission reduction projects. These projects typically have a payback period of 4-6 years or less and have a lifetime greater than 6 years.

**Strategy to realize opportunity**

Pfizer's Environmental Sustainability and Impact Reduction Standard requires all sites to develop a systematic approach to conserve energy and improve efficiency. Sites identified as medium and large energy users are required to establish environmental sustainability teams and to develop and maintain sustainability master plans that include prioritized emission reduction opportunities. Project implementation is monitored at the corporate level with performance reports provided to company leadership quarterly.

**Cost to realize opportunity**

15000000

**Comment**

---

**Identifier**

Opp3

**Where in the value chain does the opportunity occur?**

Customer

**Opportunity type**

---

Markets

**Primary climate-related opportunity driver**

Use of public-sector incentives

**Type of financial impact**

Increased revenues through access to new and emerging markets (e.g., partnerships with governments, development banks)

**Company-specific description**

Major retailers, hospitals, and other procurement programs increasingly request and rate our environmental program and recognize our outstanding achievements. Through our materiality process, we work to collect and understand the viewpoints of our stakeholders. Using the information that we have received, we have prioritized reducing emissions. For example, in 2016 Walmart added pharmaceuticals in their recognition program, greatly expanding the portion of products scored. Based on our efforts to provide product level carbon footprints, Pfizer achieved the highest recognition level, a “Giga Guru”, one of only a few pharma companies among the 131 suppliers acknowledged by the major retailer, for our Science Based Target and our publicly reported ongoing progress to address climate change.

**Time horizon**

Medium-term

**Likelihood**

Very likely

**Magnitude of impact**

Medium-low

**Are you able to provide a potential financial impact figure?**

Yes, a single figure estimate

**Potential financial impact figure (currency)**

100000000

**Potential financial impact figure – minimum (currency)**

<Not Applicable>

**Potential financial impact figure – maximum (currency)**

<Not Applicable>

**Explanation of financial impact figure**

The weighting of environmental information provided for tenders is currently a minor consideration, yet Pfizer continues to see increased interest in requests for this information for more products and by more institutional customers and retailers. Taking into consideration these requests, more than \$100MM in projected revenue for pharmaceutical products involved requests for climate change metrics and environmental sustainability efforts.

**Strategy to realize opportunity**

Pfizer has established a Product Sustainability Team and a “green claims” governance process. Beyond developing responses to tender or customer surveys, efforts to promote product achievements include developing videos for pharmacists and promotional literature and conducting lifecycle assessment comparative studies to substantiate claims reductions in GHG for the materials or processes involved.

**Cost to realize opportunity**

100000

**Comment**

Less than \$100K per year in external consultants for completing life cycle assessment studies or reviewing technical information. Internal staff completes most of the work.

---

C2.5

---

**(C2.5) Describe where and how the identified risks and opportunities have impacted your business.**

	Impact	Description
Products and services	Impacted for some suppliers, facilities, or product lines	Pfizer has leveraged our achievements in green chemistry, success with our public goals, and commitment to Science Based Targets to develop substantiated green claims which have been shared with potential customers/retailers and governmental tenders. For example, in 2016 Walmart added pharmaceuticals in their recognition program, greatly expanding the portion of products scored. Based on our efforts to provide product level carbon footprints, Pfizer achieved the highest recognition level, a "Giga Guru", one of a few pharma companies among the only 131 suppliers acknowledged by the major retailer, for our SMART Science Based Target goals and our publicly reported ongoing progress to address climate change.
Supply chain and/or value chain	Impacted for some suppliers, facilities, or product lines	Pfizer has requested 150 key suppliers to provide information on their efforts to manage greenhouse gas emissions and adopt reduction targets as indicated in our risk table. Furthermore, our cross functional Operational Risk Review process includes an assessment of climate change risk in the supply chain. In 2017 our supply chain was impacted as a result of Hurricane Maria in Puerto Rico, however dual source supply options and sufficient pre-hurricane inventory level limited the impact.
Adaptation and mitigation activities	Impacted for some suppliers, facilities, or product lines	Pfizer is assessing the impact from severe weather events and the need for adaptation and mitigation activities led by business resiliency group in Global EHS. The assessment will impact a limited subset of our operations.
Investment in R&D	Not yet impacted	As indicated in C2.4A, Pfizer continues to monitor published reports from the Center for Disease Control (CDC) and World Health Organization on projections of health impacts. Pfizer's portfolio includes many products and a wide range of medicines that might be used to treat the associated conditions.
Operations	Impacted	To achieve our public goals for greenhouse gas reductions, Pfizer has implemented numerous efficiency improvements to our operations as indicated in our emission table in our response to question C4.3b. Our operations in the Chennai, India region have been impacted by water shortages resulting from dry weather. This, combined with a poor water supply infrastructure, requires Pfizer to rely on private water suppliers to support our research and commercial sites located in the region. Pfizer sites in this region have implemented water conservation measures and arranged to obtain water from alternative sources to avoid business interruption and have also secured bottled water for drinking and hygienic purposes to ensure the safety of our colleagues.
Other, please specify	Not impacted	We have not identified any other risks and opportunities at this time.

**C2.6**

---

**(C2.6) Describe where and how the identified risks and opportunities have been factored into your financial planning process.**

	Relevance	Description
Revenues	Impacted for some suppliers, facilities, or product lines	Pfizer estimates the environmental performance information requested as part of tenders generally has about a 1% weighting in the overall procurement evaluation. The number of organizations requesting this information from suppliers continues to increase. More of our brand and commercial market leaders are asking for supporting information. The projected revenue from customers requesting this information is more than \$100M for pharmaceutical products and is factored into revenue forecasts.
Operating costs	Impacted	Annual targets are established for program savings. Mid-year and end of year environmental sustainability dashboard to the Environmental Sustainability Leadership Team identify savings achieved through efficiency improvements. Our medium and large sites are required to maintain master plans that identify opportunities for emission reductions. The costs to implement these projects as well as the expected cost savings are included in the site's operating budgets and/or capital plans as appropriate. These savings are typically around \$3-5MM per year. Projects implemented in 2018 include the installation of new boilers and HVAC systems as well as chiller optimization at several of our manufacturing sites, resulting in a savings of \$4.6MM and a 29,700 mT CO2e GHG reduction. As part of the 2025 strategy development process we are evaluating the benefits of establishing an internal carbon shadow price initiative which will be presented to program sponsors for executive approval in 2020.
Capital expenditures / capital allocation	Impacted	Pfizer locations prepare a 3- to 5-year Master Plan of projects for reducing their greenhouse gas emissions. These projects are reviewed through our capital project appropriation process. We are working to meet these goals and in 2017, approximately \$19 MM was invested in energy efficiency building services and processes and low carbon energy installations, representing an average payback of 4-6 years.
Acquisitions and divestments	Impacted for some suppliers, facilities, or product lines	Pfizer requires newly acquired facilities to establish, resource and maintain business continuity management programs.
Access to capital	Impacted	Pfizer locations prepare a 3- to 5-year Master Plan of projects for reducing their greenhouse gas emissions. These projects are reviewed through our capital project appropriation process.
Assets	Impacted for some suppliers, facilities, or product lines	Costs to maintain Pfizer's risk engineering provider is estimated at \$0.3MM annually. Costs relating to property protection and supply chain management are annualized, expected to be incurred annually and are incorporated into existing budgets. Site protection systems improvements and maintenance costs are estimated at \$0.1MM. Direct staff costs related to managing this risk is estimated at \$2.0MM.
Liabilities	Impacted for some suppliers, facilities, or product lines	Potential liabilities could arise relating to carbon taxes and/or cap-and-trade schemes.
Other	We have not identified any risks or opportunities	We have not factored any other risks and opportunities into our financial planning process.

**C3. Business Strategy**

**C3.1**

**(C3.1) Are climate-related issues integrated into your business strategy?**

Yes

**C3.1a**

**(C3.1a) Does your organization use climate-related scenario analysis to inform your business strategy?**

No, but we anticipate doing so in the next two years

**C3.1c**

### (C3.1c) Explain how climate-related issues are integrated into your business objectives and strategy.

Pfizer's Environmental Sustainability Program complements our focus on developing new therapies, driving growth and delivering value. We understand that earning society's trust is essential to our company — that to continue to develop medicines that make people's lives better we must fulfil our stakeholder commitments, be accountable for conducting business responsibly, and create and sustain deep connections with all those who are touched by our work. As a science-based healthcare company, Pfizer has fully recognizes that climate change will impact human health and as a precaution has taken voluntary efforts to reduce its GHG emissions through implementation of a Science Based Target in 2015.

Under the Environmental Sustainability Program, Pfizer's climate change strategy aligns with and enhances our overall business strategy as follows:

i) Process: Prior to 2019, Pfizer's Environmental Sustainability Council was responsible for aligning with and supporting each of the company's four strategic imperatives (<https://investors.pfizer.com/why-invest-our-story/default.aspx>). The Council set annual goals and objectives for overseeing the strategic direction of our Environmental Sustainability Program. At the beginning of 2019, Pfizer was restructured into three distinct business units. As a result, Pfizer's Environmental Sustainability governance is being refreshed in an overall effort toward simplification. Pfizer established an Environmental Sustainability 2025 Strategy Team in 2018, with representation from across our business units and functions, to develop our next generation of public sustainability goals. We will continue to execute initiatives through five platforms encompassing products, site management, supplier partnerships, colleague engagement, and public reporting and outreach. These initiatives are intended to deliver measurable business value by:

- Innovating and leading through flagship programs such as the Green Chemistry Program;
- Maximizing value through efficiency-based programs such as our Energy and Climate Change Program;
- Earning greater respect by society through reporting and disclosure, stakeholder engagement, and lessening our environmental impact; and,
- Engaging colleagues to help them own sustainability in the workplace. Metrics against these imperatives are reported to the Environmental Sustainability Council on a quarterly basis.

ii) Strategy Influence: Pfizer's environmental sustainability strategy is embedded into the business on different levels and at varying degrees depending on whether the initiative is focused on operations (e.g. manufacturing), external supply (e.g., procurement), or commercial aspects of the business (e.g., marketing). Regulatory, physical and other risks and opportunities have influenced our climate change strategy and contribute to our continued efforts to voluntarily reduce our GHG emissions; set a goal to have key suppliers set goals by 2020 to reduce their GHG emissions; and engage with stakeholders to explore markets for environmentally preferable products.

iii) Short term Strategy: Initiatives that support the business strategy short term and help to mitigate the ongoing impact of climate change: continued voluntary reductions in GHG emissions, site level energy assessments, allocating capital in the best possible way to maximize return on investment (e.g., often utility projects have the greatest return, both financially and in emission reductions), monitoring the external landscape; conducting additional assessment of the impacts of climate change on human health; engagement with key trade associations; ongoing engagement with stakeholders; and raising awareness of climate change and environmental sustainability with colleagues.

iv) Long term Strategy: Components of the longer term business strategy to help mitigate the impact of climate change include implementation of and delivery on our third generation GHG reduction goal with a long term objective of reductions aligned with scientific recommendations by 2050; implementation and delivery of our supplier sustainability goal, innovation for greener products; exploration of scope 3 emission reductions for purchased good and services; and continued focus on and assessment of climate change and health implications.

v) Strategic Advantage: From an operations perspective, energy efficiencies have afforded Pfizer strategic advantage in realizing cost savings. We would anticipate similar advantage as we execute our third GHG reduction goal and deliver on scope 3 emission reductions through 2020. From a commercial perspective and competitive advantage, we have identified several opportunities that include integrating environmental messaging into the tendering process and achieving a better understanding of sustainability around customer needs (e.g. streamlined packaging and reduced cold chain demands for Enbrel®, smaller packaging and reduced PVC for Lipitor®).

vi) Substantial Business Decisions: Carbon Pricing: Pfizer is in the process of evaluating the various mechanisms through which an internal price on carbon could be established. Public Goals: In 2013 Pfizer established public greenhouse gas, waste and water withdrawal reduction goals through the year 2020. Pfizer committed to reduce greenhouse gas emissions 20% from 2012 by 2020, building on successful past reductions of 20% from 2000 to 2007, and 35% from 2007 to 2012. We also committed to reduce our water withdrawal by 5% and the amount of waste we dispose of by 15% by 2020, compared with 2012, while meeting our increasing production requirements. In 2015 Pfizer adopted a public goal that by 2020 100% of key suppliers will manage their environmental impacts through effective sustainability programs and 90% of key suppliers will institute reduction goals for greenhouse gas emissions, waste disposal and water withdrawal. We continue to work to maximize value to our business through our focus on voluntary GHG reductions and investment in new energy saving projects. We accomplish this through implementation of our Energy and Climate Change Program. Capital Investment: In 2018, approximately \$18.4MM was invested in energy efficiency building services and processes and low carbon energy installations, representing an average payback of 4 years.

## C3.1g

---

### **(C3.1g) Why does your organization not use climate-related scenario analysis to inform your business strategy?**

i. Why scenario analysis is not currently used to inform our business strategy

Pfizer has a program for reviewing our vulnerability to potential weather-related risks at our facilities and in our supply chain. These assessments are updated periodically. At the asset level, assessment of risks is managed through Pfizer's Insurance and Business Continuity teams both at the enterprise and local level. Members from those teams participate in the risk review process that addresses Business Continuity/Resiliency and provide input on the potential impact of physical risks that may be related to climate change (e.g. severe weather events, flooding).

ii. Future plans

In 2018 Pfizer completed an assessment of acute and chronic physical risk for all our manufacturing facilities and for over 5,000 of our material suppliers. The output of this predictive analysis will support inclusion of climate-related scenario analysis into business strategy development going forward.

## C4. Targets and performance

---

### C4.1

---

#### **(C4.1) Did you have an emissions target that was active in the reporting year?**

Absolute target

#### C4.1a

---

##### **(C4.1a) Provide details of your absolute emissions target(s) and progress made against those targets.**

**Target reference number**

Abs 1

**Scope**

Scope 1+2 (location-based)

**% emissions in Scope**

100

**Targeted % reduction from base year**

20

**Base year**

2012

**Start year**

2013

**Base year emissions covered by target (metric tons CO2e)**

2131885

**Target year**

2020

**Is this a science-based target?**

Yes, this target has been approved as science-based by the Science-Based Targets initiative

**% of target achieved**

100

**Target status**

Underway

**Please explain**

We have achieved a >20% reduction, however since energy use and GHG emissions are projected to increase slightly through the remainder of the goal period due to production increases and expansions coming on line in 2018 and 2019 we are not claiming goal achievement at this time. Driving operational improvements through capital projects, operational efficiency improvements and transformative efforts (e.g., new manufacturing technology) remains the cornerstone of our focus.

---

**Target reference number**

Abs 2

**Scope**

Scope 1+2 (location-based)

**% emissions in Scope**

100

**Targeted % reduction from base year**

60

**Base year**

2000

**Start year**

2002

**Base year emissions covered by target (metric tons CO2e)**

3597487

**Target year**

2050

**Is this a science-based target?**

Yes, this target has been approved as science-based by the Science-Based Targets initiative

**% of target achieved**

89

**Target status**

Underway

---

**Please explain**

Pfizer has an aspirational goal of reducing our GHG footprint 60-80% by 2050 from a 2000 base year. To achieve this Pfizer sets shorter term goals and has previously achieved two GHG reduction goals (2000-2007 and 2007-2012). It is our intention to continue this process of setting interim goals that help drive towards this larger goal that aligns with the level of ambition needed to limit global temperature rise.

---

**C4.2**

---

**(C4.2) Provide details of other key climate-related targets not already reported in question C4.1/a/b.****Target**

Waste

**KPI – Metric numerator**

% reduction in waste disposed

**KPI – Metric denominator (intensity targets only)**

Not applicable

**Base year**

2012

**Start year**

2013

**Target year**

2020

**KPI in baseline year**

0

**KPI in target year**

15

**% achieved in reporting year**

23

**Target Status**

Underway

**Please explain**

In 2015 Pfizer established a public goal to reduce waste disposal for all sites under our operational control by 15% compared to a 2012 baseline. Because waste disposal is expected to increase through the end of the goal cycle as a result of production increases and new manufacturing operations coming on line in 2018 and 2019, we are not claiming goal achievement at this time. We have completed waste diagnostics at several of our largest sites and continue to evaluate opportunities to reduce waste generation.

**Part of emissions target**

Not applicable

**Is this target part of an overarching initiative?**

No, it's not part of an overarching initiative

---

**Target**

Other, please specify (Water)

**KPI – Metric numerator**

% reduction in water withdrawal

**KPI – Metric denominator (intensity targets only)**

Not applicable

**Base year**

2012

---

**Start year**

2013

**Target year**

2020

**KPI in baseline year**

0

**KPI in target year**

5

**% achieved in reporting year**

100

**Target Status**

Underway

**Please explain**

In 2015 Pfizer established a public goal to reduce water withdrawal excluding non-contact cooling water for all sites under our operational control by 5% compared to a 2012 baseline. Pfizer's total water withdrawal increased by 8% compared to 2017 due to increased production and the start-up of new manufacturing operations. As of the end of 2018, Pfizer's water withdrawal has decreased by 13% compared to 2012. Water withdrawal is expected to increase slightly over the next two years due to further increases in production but we fully anticipate meeting our 2020 commitment.

**Part of emissions target**

Not applicable

**Is this target part of an overarching initiative?**

No, it's not part of an overarching initiative

**Target**

Engagement with suppliers

**KPI – Metric numerator**

% of key suppliers with environmental sustainability programs

**KPI – Metric denominator (intensity targets only)**

Not applicable

**Base year**

2015

**Start year**

2016

**Target year**

2020

**KPI in baseline year**

76

**KPI in target year**

100

**% achieved in reporting year**

85

**Target Status**

Underway

**Please explain**

Key suppliers include major contributors to our external environmental footprint, including suppliers of pharmaceutical ingredients, consumer and prescription drug products, raw materials, product packaging services, key research and development collaborators, and freight forwarders. Key suppliers represent only a portion of Pfizer's overall supply chain for goods and services.

**Part of emissions target**

Not applicable

**Is this target part of an overarching initiative?**

**Target**

Engagement with suppliers

**KPI – Metric numerator**

% of key suppliers with goals in place to reduce GHG emissions, waste disposal and water withdrawal

**KPI – Metric denominator (intensity targets only)**

Not applicable

**Base year**

2015

**Start year**

2016

**Target year**

2020

**KPI in baseline year**

51

**KPI in target year**

90

**% achieved in reporting year**

53

**Target Status**

Underway

**Please explain**

Key suppliers include major contributors to our external environmental footprint, including suppliers of pharmaceutical ingredients, consumer and prescription drug products, raw materials, product packaging services, key research and development collaborators, and freight forwarders. Key suppliers represent only a portion of Pfizer's overall supply chain for goods and services.

**Part of emissions target**

Not applicable

**Is this target part of an overarching initiative?**

Science-based targets initiative

C4.3

**(C4.3) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.**

Yes

C4.3a

**(C4.3a) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.**

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e (only for rows marked *)
Under investigation	316	153117.87
To be implemented*	124	131700.32
Implementation commenced*	31	9407.75
Implemented*	143	29701.04
Not to be implemented	81	10021.39

### C4.3b

---

**(C4.3b) Provide details on the initiatives implemented in the reporting year in the table below.**

**Initiative type**

Energy efficiency: Building services

**Description of initiative**

Other, please specify (HVAC, lighting and other improvements)

**Estimated annual CO2e savings (metric tonnes CO2e)**

29701

**Scope**

Scope 2 (location-based)

**Voluntary/Mandatory**

Voluntary

**Annual monetary savings (unit currency – as specified in C0.4)**

5292072

**Investment required (unit currency – as specified in C0.4)**

19047293

**Payback period**

1-3 years

**Estimated lifetime of the initiative**

6-10 years

**Comment**

---

**Initiative type**

Low-carbon energy purchase

**Description of initiative**

Wind

**Estimated annual CO2e savings (metric tonnes CO2e)**

44472

**Scope**

Scope 2 (market-based)

**Voluntary/Mandatory**

Voluntary

**Annual monetary savings (unit currency – as specified in C0.4)**

200000

**Investment required (unit currency – as specified in C0.4)**

0

**Payback period**

<1 year

**Estimated lifetime of the initiative**

1-2 years

**Comment**

---

### C4.3c

---

**(C4.3c) What methods do you use to drive investment in emissions reduction activities?**

Method	Comment
Compliance with regulatory requirements/standards	Pfizer priorities funding for projects that reduce energy and GHG emissions associated with regulatory compliance requirements.
Internal incentives/recognition programs	Pfizer's internal awards program called "Safety and Sustainability STAR Awards" are given to employees for projects across Pfizer related to driving a safety cultural, energy and climate change, and green biotech and chemistry. These awards encourage sites to implement sustainability initiatives. In 2018, 8 projects were awarded STARS for environmental sustainability achievements.
Lower return on investment (ROI) specification	Projects are evaluated based on ROI. The benefits of reducing GHG emissions are considered when Pfizer is evaluating projects with potential for similar savings.

**C4.5**

---

**(C4.5) Do you classify any of your existing goods and/or services as low-carbon products or do they enable a third party to avoid GHG emissions?**

No

**C5. Emissions methodology**

---

**C5.1**

---

**(C5.1) Provide your base year and base year emissions (Scopes 1 and 2).**

**Scope 1**

**Base year start**

January 1 2012

**Base year end**

December 31 2012

**Base year emissions (metric tons CO2e)**

1073103

**Comment**

Base year emissions were updated in 2018 due to a baseline adjustment to account for the divestiture of several manufacturing sites.

**Scope 2 (location-based)**

**Base year start**

January 1 2012

**Base year end**

December 31 2012

**Base year emissions (metric tons CO2e)**

1058782

**Comment**

Base year emissions were updated in 2018 due to a baseline adjustment to account for the divestiture of several manufacturing sites.

**Scope 2 (market-based)**

**Base year start**

January 1 2012

**Base year end**

December 31 2012

**Base year emissions (metric tons CO2e)**

1058782

**Comment**

The location-based result has been used as a proxy since a market-based method did not exist in 2012 and the figure cannot be calculated.

**C5.2**

---

**(C5.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate Scope 1 and Scope 2 emissions.**

The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)

**C6. Emissions data**

---

**C6.1**

---

**(C6.1) What were your organization's gross global Scope 1 emissions in metric tons CO2e?**

**Reporting year**

**Gross global Scope 1 emissions (metric tons CO2e)**

756964

**Start date**

January 1 2018

**End date**

December 31 2018

**Comment**

**Past year 1**

**Gross global Scope 1 emissions (metric tons CO2e)**

788838

**Start date**

January 1 2017

**End date**

December 31 2017

**Comment**

**C6.2**

---

**(C6.2) Describe your organization's approach to reporting Scope 2 emissions.**

**Row 1**

**Scope 2, location-based**

We are reporting a Scope 2, location-based figure

**Scope 2, market-based**

We are reporting a Scope 2, market-based figure

**Comment**

Market-based factors are limited to electrical consumption in Ireland and for our manufacturing facilities in Sweden and Spain.

**C6.3**

---

**(C6.3) What were your organization's gross global Scope 2 emissions in metric tons CO2e?**

**Reporting year**

**Scope 2, location-based**

919786

**Scope 2, market-based (if applicable)**

905002

**Start date**

January 1 2018

**End date**

December 31 2018

**Comment**

**Past year 1**

**Scope 2, location-based**

859691

**Scope 2, market-based (if applicable)**

812923

**Start date**

January 1 2017

**End date**

December 31 2017

**Comment**

**C6.4**

---

**(C6.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions that are within your selected reporting boundary which are not included in your disclosure?**

Yes

**C6.4a**

---

**(C6.4a) Provide details of the sources of Scope 1 and Scope 2 emissions that are within your selected reporting boundary which are not included in your disclosure.**

**Source**

Emissions from fermentation

**Relevance of Scope 1 emissions from this source**

Emissions are not relevant

**Relevance of location-based Scope 2 emissions from this source**

Emissions are not relevant

**Relevance of market-based Scope 2 emissions from this source (if applicable)**

Emissions are not relevant

**Explain why this source is excluded**

Emissions from fermentation are very low; estimated to be well under 1% of the global footprint.

---

**C6.5**

---

## **(C6.5) Account for your organization's Scope 3 emissions, disclosing and explaining any exclusions.**

### **Purchased goods and services**

#### **Evaluation status**

Relevant, calculated

#### **Metric tonnes CO2e**

1562024

#### **Emissions calculation methodology**

Apportioned emissions data collected from key contract manufacturers and suppliers of raw materials and packaging. Emissions for goods and services not covered by supply chain survey estimated based on spend using DEFRA Table 13 emission factors adjusted for inflation.

#### **Percentage of emissions calculated using data obtained from suppliers or value chain partners**

24

#### **Explanation**

The emissions data received directly from suppliers reflects the 2017 reporting year as annual data for 2018 will not be available until later in the year. Pfizer's target date for completion of supply chain data collection is July 31, 2019.

### **Capital goods**

#### **Evaluation status**

Relevant, calculated

#### **Metric tonnes CO2e**

855794

#### **Emissions calculation methodology**

Estimated based on spend using DEFRA Table 13 emission factors adjusted for inflation.

#### **Percentage of emissions calculated using data obtained from suppliers or value chain partners**

0

#### **Explanation**

### **Fuel-and-energy-related activities (not included in Scope 1 or 2)**

#### **Evaluation status**

Relevant, calculated

#### **Metric tonnes CO2e**

265780

#### **Emissions calculation methodology**

Calculated using Pfizer's fuel and electricity data and DEFRA (UK) Well-to-Tank (WTT) and Transmission and distribution emission factors (<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2018>).

#### **Percentage of emissions calculated using data obtained from suppliers or value chain partners**

0

#### **Explanation**

### **Upstream transportation and distribution**

#### **Evaluation status**

Relevant, calculated

#### **Metric tonnes CO2e**

416416

#### **Emissions calculation methodology**

Calculated from shipping data using mass of goods, distance travelled and 2018 US EPA Climate Leaders GHG emission factors ([https://www.epa.gov/sites/production/files/2018-03/documents/emission-factors\\_mar\\_2018\\_0.pdf](https://www.epa.gov/sites/production/files/2018-03/documents/emission-factors_mar_2018_0.pdf)).

#### **Percentage of emissions calculated using data obtained from suppliers or value chain partners**

100

#### **Explanation**

## Waste generated in operations

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

11667

### Emissions calculation methodology

Calculated using mass of waste and DEFRA emission factors by disposal method (<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2018>).

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### Explanation

## Business travel

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

347533

### Emissions calculation methodology

Air travel calculated based on distance travelled and class of service using DEFRA emission factors (<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2018>). Rental car use and hotel stays estimated by Pfizer's travel agency following Greenhouse Gas Protocol methodology. Emissions estimated for US intercity rail travel (Amtrak) using 2018 US EPA Climate Leaders GHG emission factors ([https://www.epa.gov/sites/production/files/2018-03/documents/emission-factors\\_mar\\_2018\\_0.pdf](https://www.epa.gov/sites/production/files/2018-03/documents/emission-factors_mar_2018_0.pdf)).

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

### Explanation

Data is not available for train travel outside the United States.

## Employee commuting

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

92869

### Emissions calculation methodology

Estimated using number of employees, average commute distance, and estimated number of commute days and DEFRA emission factors (<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2018>).

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### Explanation

## Upstream leased assets

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

35444

### Emissions calculation methodology

Leased facility square footage derived from corporate real estate database. Estimate generated using the Greenhouse Gas Protocol/Quantis Scope 3 Evaluator.

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### Explanation

## Downstream transportation and distribution

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

85059

### Emissions calculation methodology

Estimated based on number of products sold and average distance of travel to medical offices, pharmacies and retailers using DEFRA emission factors (<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2018>).

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### Explanation

Estimate based on US sales of prescription medications and consumer products only.

## Processing of sold products

### Evaluation status

Not relevant, explanation provided

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Pfizer products are not further processed in significant quantities.

## Use of sold products

### Evaluation status

Not relevant, explanation provided

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Pfizer products are not likely to create significant emissions in normal use.

## End of life treatment of sold products

### Evaluation status

Not relevant, explanation provided

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Pfizer products are intended to be ingested by humans. Products returned to Pfizer for destruction by Pfizer are accounted for in waste treatment estimate.

## Downstream leased assets

### Evaluation status

Not relevant, explanation provided

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Pfizer was not a significant real estate lessor in 2018.

## Franchises

### Evaluation status

Not relevant, explanation provided

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Pfizer does not operate franchises.

## Investments

### Evaluation status

Relevant, calculated

### Metric tonnes CO2e

7969

### Emissions calculation methodology

Energy consumption data is provided by the site for entry into our Enablon system. Facility Scope 1+2 emissions are calculated by the same methodology as is used for internal operations.

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

### Explanation

## Other (upstream)

### Evaluation status

Not evaluated

### Metric tonnes CO2e

<Not Applicable>

### Emissions calculation methodology

<Not Applicable>

### Percentage of emissions calculated using data obtained from suppliers or value chain partners

<Not Applicable>

### Explanation

Scope 3 emissions adequately captured by standard categories.

**Other (downstream)**

**Evaluation status**

Not evaluated

**Metric tonnes CO2e**

<Not Applicable>

**Emissions calculation methodology**

<Not Applicable>

**Percentage of emissions calculated using data obtained from suppliers or value chain partners**

<Not Applicable>

**Explanation**

Scope 3 emissions adequately captured by standard categories.

C6.7

---

**(C6.7) Are carbon dioxide emissions from biologically sequestered carbon relevant to your organization?**

Yes

C6.7a

---

**(C6.7a) Provide the emissions from biologically sequestered carbon relevant to your organization in metric tons CO2.**

**Row 1**

**Emissions from biologically sequestered carbon (metric tons CO2)**

207

**Comment**

C6.10

---

**(C6.10) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.**

**Intensity figure**

0.00003126

**Metric numerator (Gross global combined Scope 1 and 2 emissions)**

1676749

**Metric denominator**

unit total revenue

**Metric denominator: Unit total**

5364700000

**Scope 2 figure used**

Location-based

**% change from previous year**

0.5

**Direction of change**

Decreased

**Reason for change**

Pfizer's emissions increased in 2018 due to increased production, both the start-up of new manufacturing operations and a return to normal operations for our Puerto Rico facilities that were shut down in Q4 2017. Our revenue also increased, however, resulting in a net decrease in tons CO2e per unit revenue.

**C7. Emissions breakdowns**

**C7.1**

**(C7.1) Does your organization break down its Scope 1 emissions by greenhouse gas type?**

Yes

**C7.1a**

**(C7.1a) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used greenhouse warming potential (GWP).**

Greenhouse gas	Scope 1 emissions (metric tons of CO2e)	GWP Reference
CO2	694830	IPCC Fifth Assessment Report (AR5 – 100 year)
CH4	542	IPCC Fifth Assessment Report (AR5 – 100 year)
N2O	1995	IPCC Fifth Assessment Report (AR5 – 100 year)
SF6	621	Other, please specify (IPCC AR2)
HFCs	41615.86	Other, please specify (IPCC AR2)
Other, please specify (VOC)	12671	Other, please specify (Internal factor)

**C7.2**

**(C7.2) Break down your total gross global Scope 1 emissions by country/region.**

Country/Region	Scope 1 emissions (metric tons CO2e)
United States of America	366986
Puerto Rico	33856
Ireland	67341
India	29270
China	7202
Italy	44893
Other, please specify (Rest of World)	177416

**C7.3**

**(C7.3) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.**

By business division

**C7.3a**

**(C7.3a) Break down your total gross global Scope 1 emissions by business division.**

Business division	Scope 1 emissions (metric ton CO2e)
Commercial Offices	31260
Logistics	3355
Pfizer Global Supply (Manufacturing)	446865
Research and Development	139412
Fleet	114288
Other sites	21782

**C7.5**

**(C7.5) Break down your total gross global Scope 2 emissions by country/region.**

Country/Region	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)	Purchased and consumed electricity, heat, steam or cooling (MWh)	Purchased and consumed low-carbon electricity, heat, steam or cooling accounted in market-based approach (MWh)
United States of America	478038	507367	1120066	0
Puerto Rico	107497	107497	160176	0
Ireland	44365	0	105865	105865
India	77907	77907	100471	0
China	58653	58653	127736	0
Italy	7242	7242	21058	0
Other, please specify (Rest of World)	146086	146337	438219	17017

**C7.6**

**(C7.6) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.**

By business division

**C7.6a**

**(C7.6a) Break down your total gross global Scope 2 emissions by business division.**

Business division	Scope 2, location-based emissions (metric tons CO2e)	Scope 2, market-based emissions (metric tons CO2e)
Commercial offices	41036	41036
Logistics	7391	7391
Pfizer Global Supply (Manufacturing)	753839	716896
Research and Development	71645	93804
Other sites	45875	45875

**C7.9**

**(C7.9) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?**

Increased

**C7.9a**

**(C7.9a) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined) and for each of them specify how your emissions compare to the previous year.**

	Change in emissions (metric tons CO2e)	Direction of change	Emissions value (percentage)	Please explain calculation
Change in renewable energy consumption	0	No change	0	Pfizer did not achieve emission reductions associated with changes in renewable energy consumption in 2018.
Other emissions reduction activities	29701	Decreased	1.8	Emission reductions activities and plant network changes to optimize operations. Calculation: method: Total reduction achieved in 2018/(2017 Total Scope 1 + 2 Location Based)= 29,701/1,643,195
Divestment	0	No change	0	Not applicable
Acquisitions	0	No change	0	Not applicable
Mergers	0	No change	0	Not applicable
Change in output		<Not Applicable>		
Change in methodology	0	No change	0	Not applicable
Change in boundary	0	No change	0	Not applicable
Change in physical operating conditions	0	No change	0	Not applicable
Unidentified	0	No change	0	Not applicable
Other	0	No change	0	Not applicable

**C7.9b**

**(C7.9b) Are your emissions performance calculations in C7.9 and C7.9a based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?**

Location-based

**C8. Energy**

**C8.1**

**(C8.1) What percentage of your total operational spend in the reporting year was on energy?**

More than 0% but less than or equal to 5%

**C8.2**

**(C8.2) Select which energy-related activities your organization has undertaken.**

	Indicate whether your organization undertakes this energy-related activity
Consumption of fuel (excluding feedstocks)	Yes
Consumption of purchased or acquired electricity	Yes
Consumption of purchased or acquired heat	Yes
Consumption of purchased or acquired steam	Yes
Consumption of purchased or acquired cooling	Yes
Generation of electricity, heat, steam, or cooling	Yes

**C8.2a**

**(C8.2a) Report your organization's energy consumption totals (excluding feedstocks) in MWh.**

	Heating value	MWh from renewable sources	MWh from non-renewable sources	Total MWh
Consumption of fuel (excluding feedstock)	HHV (higher heating value)	52401	3532250	3584650
Consumption of purchased or acquired electricity	<Not Applicable>	115773	1500755	1616528
Consumption of purchased or acquired heat	<Not Applicable>	1087	1810	2897
Consumption of purchased or acquired steam	<Not Applicable>	15930	377657	393587
Consumption of purchased or acquired cooling	<Not Applicable>	0	60579	60579
Consumption of self-generated non-fuel renewable energy	<Not Applicable>	0	<Not Applicable>	0
Total energy consumption	<Not Applicable>	185191	5473051	5658241

**C8.2b**

**(C8.2b) Select the applications of your organization's consumption of fuel.**

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for the generation of electricity	Yes
Consumption of fuel for the generation of heat	Yes
Consumption of fuel for the generation of steam	Yes
Consumption of fuel for the generation of cooling	No
Consumption of fuel for co-generation or tri-generation	Yes

**C8.2c**

---

**(C8.2c) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.**

**Fuels (excluding feedstocks)**

Biodiesel

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

1708

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Coal

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

77498

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

77498

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Fuel Oil Number 2

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

50507

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

50507

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Kerosene

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

108158

**MWh fuel consumed for self-generation of electricity**

24323

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

83814

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Natural Gas

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

2737326

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

1793941

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

943385

**Comment**

---

**Fuels (excluding feedstocks)**

Liquefied Petroleum Gas (LPG)

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

118667

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

118667

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Wood Pellets

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

6075

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

6075

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Diesel

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

120034

**MWh fuel consumed for self-generation of electricity**

---

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Other, please specify (Ethanol (E100))

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

2060

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Other, please specify (Ethanol (E75))

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

184

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Other, please specify (Ethanol (E85))

---

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

159

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Motor Gasoline

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

270696

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Jet Kerosene

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

45252

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

0

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

---

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

**Fuels (excluding feedstocks)**

Wood Chips

**Heating value**

LHV (lower heating value)

**Total fuel MWh consumed by the organization**

46326

**MWh fuel consumed for self-generation of electricity**

0

**MWh fuel consumed for self-generation of heat**

0

**MWh fuel consumed for self-generation of steam**

46326

**MWh fuel consumed for self-generation of cooling**

<Not Applicable>

**MWh fuel consumed for self-cogeneration or self-trigeneration**

0

**Comment**

---

## C8.2d

---

**(C8.2d) List the average emission factors of the fuels reported in C8.2c.**

**Biodiesel**

**Emission factor**

0.00025

**Unit**

metric tons CO<sub>2</sub>e per MWh

**Emission factor source**

GHG Protocol

**Comment**

Emission factor = 0.000252075

**Coal**

**Emission factor**

0.00032

**Unit**

metric tons CO<sub>2</sub> per MWh

**Emission factor source**

GHG Protocol

**Comment**

Emission factor = 0.000320684

## Diesel

### Emission factor

0.00026

### Unit

metric tons CO<sub>2</sub>e per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000261898

## Fuel Oil Number 2

### Emission factor

0.00026

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000257194

## Jet Kerosene

### Emission factor

0.00026

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000262029

## Kerosene

### Emission factor

0.00025

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000253257

## Liquefied Petroleum Gas (LPG)

### Emission factor

0.00023

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000227162

## Motor Gasoline

### Emission factor

0.00024

### Unit

metric tons CO<sub>2</sub>e per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000244154

## Natural Gas

### Emission factor

0.00018

### Unit

metric tons CO<sub>2</sub>e per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 0.000181234

## Wood Chips

### Emission factor

0

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor = 3.94306E-06

## Wood Pellets

### Emission factor

0

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Emission factor 3.94299E-06

## Other

### Emission factor

0.00024

### Unit

metric tons CO<sub>2</sub> per MWh

### Emission factor source

GHG Protocol

### Comment

Ethanol E100 Emission factor = 0.000249953 Ethanol E75 Emission factor = 0.000248035 Ethanol E85 Emission factor = 0.00024875

## C8.2e

---

**(C8.2e)** Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.

	Total Gross generation (MWh)	Generation that is consumed by the organization (MWh)	Gross generation from renewable sources (MWh)	Generation from renewable sources that is consumed by the organization (MWh)
Electricity	184020	168503	4149	179872
Heat	0	0	0	0
Steam	0	0	0	0
Cooling	0	0	0	0

## C8.2f

---

**(C8.2f)** Provide details on the electricity, heat, steam and/or cooling amounts that were accounted for at a low-carbon emission factor in the market-based Scope 2 figure reported in C6.3.

**Basis for applying a low-carbon emission factor**

Contract with suppliers or utilities (e.g. green tariff), not supported by energy attribute certificates

**Low-carbon technology type**

Wind

**Region of consumption of low-carbon electricity, heat, steam or cooling**

Europe

**MWh consumed associated with low-carbon electricity, heat, steam or cooling**

105865

**Emission factor (in units of metric tons CO<sub>2</sub>e per MWh)**

0

**Comment**

Wind-generated electricity

---

**Basis for applying a low-carbon emission factor**

Energy attribute certificates, Guarantees of Origin

**Low-carbon technology type**

Wind

**Region of consumption of low-carbon electricity, heat, steam or cooling**

Europe

**MWh consumed associated with low-carbon electricity, heat, steam or cooling**

9908

**Emission factor (in units of metric tons CO<sub>2</sub>e per MWh)**

0

**Comment**

Wind-generated electricity

---

## C9. Additional metrics

---

### C9.1

---

**(C9.1) Provide any additional climate-related metrics relevant to your business.**

**Description**

Waste

**Metric value**

98751184

**Metric numerator**

kg

**Metric denominator (intensity metric only)**

Not applicable

**% change from previous year**

1

**Direction of change**

Decreased

**Please explain**

Pfizer has set a 2020 waste disposal reduction goal of 15% compared to a 2012 baseline. As of 2018, Pfizer has reduced waste disposed by 22% compared to the 2012 baseline.

---

**Description**

Other, please specify (Water withdrawal (excluding NCCW) )

**Metric value**

16337000

**Metric numerator**

cubic meters

**Metric denominator (intensity metric only)**

Not applicable

**% change from previous year**

5

**Direction of change**

Increased

**Please explain**

Pfizer has set a 2020 water withdrawal (excluding non-contact cooling water) reduction goal of 5% compared to a 2012 baseline. Water withdrawal increased in 2018 in part due to several sites being unable to operate in Q4 2017 due to Hurricane Maria and also because several new manufacturing facilities came online in 2018. As of 2018, Pfizer has reduced water withdrawal by 13% compared to the 2012 baseline.

---

**C10. Verification**

---

**C10.1**

---

**(C10.1) Indicate the verification/assurance status that applies to your reported emissions.**

	Verification/assurance status
Scope 1	Third-party verification or assurance process in place
Scope 2 (location-based or market-based)	Third-party verification or assurance process in place
Scope 3	Third-party verification or assurance process in place

---

## C10.1a

---

**(C10.1a) Provide further details of the verification/assurance undertaken for your Scope 1 and/or Scope 2 emissions and attach the relevant statements.**

**Scope**

Scope 1

**Verification or assurance cycle in place**

Annual process

**Status in the current reporting year**

Underway but not complete for reporting year-previous statement of process attached

**Type of verification or assurance**

Limited assurance

**Attach the statement**

Pfizer EY2017 CDP Letter Final Issued 20190718.pdf

**Page/ section reference**

Page 3 item 5

**Relevant standard**

ISO14064-3

**Proportion of reported emissions verified (%)**

100

---

**Scope**

Scope 2 location-based

**Verification or assurance cycle in place**

Annual process

**Status in the current reporting year**

Underway but not complete for reporting year-previous statement of process attached

**Type of verification or assurance**

Limited assurance

**Attach the statement**

Pfizer EY2017 CDP Letter Final Issued 20190718.pdf

**Page/ section reference**

Page 3 item 5

**Relevant standard**

ISO14064-3

**Proportion of reported emissions verified (%)**

100

---

## C10.1b

---

**(C10.1b) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.**

**Scope**

Scope 3- at least one applicable category

**Verification or assurance cycle in place**

Annual process

**Status in the current reporting year**

Underway but not complete for reporting year – previous statement of process attached

**Attach the statement**

Pfizer EY2017 CDP Letter Final Issued 20190718.pdf

**Page/section reference**

Page 3 item 5

**Relevant standard**

ISO14064-3

---

**C10.2**

---

**(C10.2) Do you verify any climate-related information reported in your CDP disclosure other than the emissions figures reported in C6.1, C6.3, and C6.5?**

In progress

**C11. Carbon pricing**

---

**C11.1**

---

**(C11.1) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?**

Yes

**C11.1a**

---

**(C11.1a) Select the carbon pricing regulation(s) which impacts your operations.**

EU ETS

Ireland carbon tax

Other carbon tax, please specify (UK CRC)

**C11.1b**

---

(C11.1b) Complete the following table for each of the emissions trading systems in which you participate.

**EU ETS**

**% of Scope 1 emissions covered by the ETS**

12

**Period start date**

January 1 2018

**Period end date**

December 31 2018

**Allowances allocated**

53509

**Allowances purchased**

24036

**Verified emissions in metric tons CO2e**

86072

**Details of ownership**

Facilities we own and operate

**Comment**

C11.1c

---

(C11.1c) Complete the following table for each of the tax systems in which you participate.

**Ireland carbon tax**

**Period start date**

January 1 2018

**Period end date**

December 31 2018

**% of emissions covered by tax**

14.8

**Total cost of tax paid**

1403091

**Comment**

**Other carbon tax, please specify**

**Period start date**

April 1 2017

**Period end date**

March 31 2018

**% of emissions covered by tax**

0.4

**Total cost of tax paid**

161844

**Comment**

C11.1d

---

**(C11.1d) What is your strategy for complying with the systems in which you participate or anticipate participating?**

Pfizer's strategy is to set corporate carbon reduction goals which in turn drives the sites which are participating in these schemes to implement energy reduction projects and equipment upgrades to reduce their carbon footprint. An example of this is the optimization of HVAC systems implemented at our Grange Castle facility. In the past 3 years 12 HVAC optimization projects have been implemented which combined have reduced CO2 emissions by 1500 tonnes annually. This in turn reduces the annual EUETS credits required.

**C11.2**

---

**(C11.2) Has your organization originated or purchased any project-based carbon credits within the reporting period?**

No

**C11.3**

---

**(C11.3) Does your organization use an internal price on carbon?**

No, but we anticipate doing so in the next two years

**C12. Engagement**

---

**C12.1**

---

**(C12.1) Do you engage with your value chain on climate-related issues?**

Yes, our suppliers

**C12.1a**

---

**(C12.1a) Provide details of your climate-related supplier engagement strategy.**

**Type of engagement**

Information collection (understanding supplier behavior)

**Details of engagement**

Other, please specify (Collect information on environmental sustainability programs, energy use, GHG emissions and emission/energy reduction goals)

**% of suppliers by number**

10

**% total procurement spend (direct and indirect)**

60

**% Scope 3 emissions as reported in C6.5**

10.3

**Rationale for the coverage of your engagement**

Leveraging published industry and company life cycle assessments (LCA), Pfizer identified the leading suppliers in the major product categories accounting for largest scope 3 environmental impacts – 45% manufacturing operations; 25% raw material suppliers; 25% packaging materials; and 1% transportation vendors. There was a clear delineation that working with the top 150 suppliers in these categories would maximize our impact.

**Impact of engagement, including measures of success**

In 2015 Pfizer Executive Leadership endorsed public supplier sustainability goal targeting that by 2020 all key suppliers will track greenhouse gas, waste and water; and 90% will institute reduction goals. The Pfizer Annual Review publishes results of the annual supplier survey which indicates progress year on year. In 2018, 85% of suppliers track emissions and 53% established reduction goals. Pfizer is aiding suppliers to find help to reduce GHG emissions through an external firm, Globality.

**Comment**

Percent of suppliers by number estimated. Pfizer has been leading an industry effort to standardize sustainability survey questions to suppliers. Because of the overlap of suppliers used, the coordination will ease burden on suppliers and has already increased supplier participation rates.

---

**C12.3**

---

**(C12.3) Do you engage in activities that could either directly or indirectly influence public policy on climate-related issues through any of the following?**

- Trade associations
- Funding research organizations
- Other

**C12.3b**

---

**(C12.3b) Are you on the board of any trade associations or do you provide funding beyond membership?**

Yes

**C12.3c**

---

**(C12.3c) Enter the details of those trade associations that are likely to take a position on climate change legislation.**

**Trade association**

Business Roundtable

**Is your position on climate change consistent with theirs?**

Mixed

**Please explain the trade association's position**

---

Business Roundtable's position on climate change can be found on its website (<https://www.businessroundtable.org/policy-perspectives/energy-environment>): "Access to sustainable, reliable, affordable energy is fundamental to U.S. national and economic security. Similarly, a clean and healthy environment is essential for economic prosperity now and in the long term. Business Roundtable supports policies that build on America's strengths in technology and energy diversity, encourage investment and innovation in our nation's vibrant energy sector, and preserve environmental quality for the 21st century and beyond."

**How have you influenced, or are you attempting to influence their position?**

Pfizer participated in the 2017 Business Roundtable Sustainability Report, whereby CEOs shared how their companies have put people and technology to work to improve the quality of life in communities across America and around the world.

---

**Trade association**

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

**Is your position on climate change consistent with theirs?**

Consistent

**Please explain the trade association's position**

The IFPMA recognizes the link between climate change and human health. <http://www.ifpma.org/resource-centre/ifpma-statement-on-climate-change-and-health-2/>.

**How have you influenced, or are you attempting to influence their position?**

Pfizer has long recognized the link between climate change and health:

[http://www.pfizer.com/files/responsibility/protecting\\_environment/Climate\\_Change\\_and\\_Human\\_Health.pdf](http://www.pfizer.com/files/responsibility/protecting_environment/Climate_Change_and_Human_Health.pdf) Pfizer's position on climate change can also be found here: [https://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer-Climate-Change-Position-Statement.pdf](https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf)

---

**Trade association**

NAM

**Is your position on climate change consistent with theirs?**

Mixed

**Please explain the trade association's position**

NAM's position on energy and GHG regulation can be found on the NAM webpage (<https://www.nam.org/issue/environment/>) and in their Environment Agenda (<https://www.nam.org/wp-content/uploads/2019/05/PolicyWhitePaper-Environment.pdf>).

**How have you influenced, or are you attempting to influence their position?**

Pfizer shared its Climate Change Position Statement with NAM leadership. Pfizer's position on climate change can be found here: [https://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer-Climate-Change-Position-Statement.pdf](https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf).

---

**Trade association**

American Legislative Exchange Council (ALEC).

**Is your position on climate change consistent with theirs?**

Mixed

**Please explain the trade association's position**

ALEC Energy Principles can be found on the website <https://www.alec.org/model-policy/alec-energy-principles/>

**How have you influenced, or are you attempting to influence their position?**

For its December 2017 session, ALEC had proposed an objectionable resolution to reopen the Environmental Protection Agency's 2009 endangerment finding for greenhouse gases. Before this session, Pfizer worked hard to defeat the resolution because it conflicted with our vision of responsible environmental actions and sought to undermine efforts to address the critical issue of climate change. As a result of the engagement of companies such as ours, the resolution was rightfully withdrawn. We are pleased with that outcome. Had Pfizer not been engaged within ALEC, we would not have had the chance to make our position known and be an agent of change. – Opinion Section Washington Post, December 20, 2017 by Ken Cole, Sr. Vice President US Government Relations. [https://www.washingtonpost.com/opinions/pfizer-and-upss-victory-on-climate-change/2017/12/19/eafd79c4-e43d-11e7-833f-155031558ff4\\_story.html?noredirect=on&utm\\_term=.2a0240545652](https://www.washingtonpost.com/opinions/pfizer-and-upss-victory-on-climate-change/2017/12/19/eafd79c4-e43d-11e7-833f-155031558ff4_story.html?noredirect=on&utm_term=.2a0240545652). Pfizer has continued to engage with ALEC and vote on resolutions in a manner aligned and consistent with our company's climate change position statement ([https://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer-Climate-Change-Position-Statement.pdf](https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf)).

---

**Trade association**

US Chamber of Commerce

**Is your position on climate change consistent with theirs?**

Mixed

---

**Please explain the trade association's position**

The U.S. Chamber of Commerce (Chamber) states their policy position on climate change on the Chamber website (<https://www.uschamber.com/addressing-climate-change>): "The climate is changing and humans are contributing to these changes. We believe that there is much common ground on which all sides of this discussion could come together to address climate change with policies that are practical, flexible, predictable, and durable. We believe in a policy approach that acknowledges the costs of action and inaction and the competitiveness of the U.S." economy.

**How have you influenced, or are you attempting to influence their position?**

Pfizer is one of a number of "like-minded" companies that established the Climate Solutions Working Group (CSWG) in 2017 for the purpose of advancing business interests in climate change solutions and clean energy markets. The CSWG worked with the U.S Chamber of Commerce to influence the Chamber's recently released climate policy statement. The statement, while a document of compromise, makes clear that climate change is a serious issue, a risk to businesses, and that inaction is not an option.

---

**Trade association**

International Chamber of Commerce (ICC)

**Is your position on climate change consistent with theirs?**

Mixed

**Please explain the trade association's position**

The ICC position on climate change and desired outcomes from COP24 can be found on its website: <https://iccwbo.org/global-issues-trends/responsible-business/climate-change/>.

**How have you influenced, or are you attempting to influence their position?**

Pfizer's position on climate change can be found here: [https://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer-Climate-Change-Position-Statement.pdf](https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf).

---

**Trade association**

Numerous other trade associations across the globe

**Is your position on climate change consistent with theirs?**

Unknown

**Please explain the trade association's position**

Pfizer is a member of many trade associations across the world focusing on pharma, consumer health, medical and vaccine issues. We also work with numerous general business associations (such as Chambers of Commerce) and other public policy groups. We detail above the positions relating to a sample of certain trade associations of which we are a member; however, given the large number of groups involved we are unable to provide details on the climate change position of each and every group.

**How have you influenced, or are you attempting to influence their position?**

Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups. However, Pfizer works in good faith with these organizations to make its position on climate change and other environmental issues known.

---

**C12.3d**

---

**(C12.3d) Do you publicly disclose a list of all research organizations that you fund?**

Yes

**C12.3e**

---

**(C12.3e) Provide details of the other engagement activities that you undertake.**

Pfizer was a corporate sponsor of The Climate Group's NYC Climate Week in September 2018. Climate Week NYC is a week of events, conferences and other activities aimed at raising awareness about climate change and to bringing together leaders from business and government to discuss solutions to mitigate climate change. Pfizer was invited to participate in CDP's 2018 Stories of Change publication and sponsored CDP's Spring 2019 workshop. Pfizer is also an active member of the World Resources Institute's Corporate Consultative Group through which we gain insights into climate change policy, GHG accounting, water risk mapping, and other sustainability matters as well as share our expertise and experience on these issues. Pfizer is also a member of Business for Social Responsibility. In December 2015, Pfizer joined the Science Based Target (SBT) initiative as a company that had already established a SBT. At the time, Pfizer was one of only a handful of companies to receive this recognition for its existing goal, which was developed in 2012.

**C12.3f**

---

**(C12.3f) What processes do you have in place to ensure that all of your direct and indirect activities that influence policy are consistent with your overall climate change strategy?**

Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large in an effort to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups. However, Pfizer works in good faith with these organizations to make its position on climate change and other environmental issues known.

REF: [http://www.pfizer.com/responsibility/grants\\_contributions/lobbying\\_and\\_political\\_contributions.jsp](http://www.pfizer.com/responsibility/grants_contributions/lobbying_and_political_contributions.jsp)

Information related to criteria used for third party funding may be found at: [http://www.pfizer.com/files/third\\_party\\_funding\\_criteria.pdf](http://www.pfizer.com/files/third_party_funding_criteria.pdf)

Pfizer's Climate Change Position Statement is attached and may be found at:

[http://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer\\_Climate\\_Change\\_Position\\_Statement.pdf](http://www.pfizer.com/files/responsibility/protecting_environment/Pfizer_Climate_Change_Position_Statement.pdf)

**C12.4**

---

**(C12.4) Have you published information about your organization's response to climate change and GHG emissions performance for this reporting year in places other than in your CDP response? If so, please attach the publication(s).**

**Publication**

In mainstream reports

**Status**

Complete

**Attach the document**

pfizer-2018-annual-review-performance-data.pdf

**Page/Section reference**

P51

**Content elements**

Emissions figures

Emission targets

Other metrics

Other, please specify (Supply chain performance results )

**Comment**

Performance section of report attached (also posted separately online). Full report available at [https://www.pfizer.com/files/investors/financial\\_reports/annual\\_reports/2018/assets/pdf/pfizer-2018-annual-review.pdf](https://www.pfizer.com/files/investors/financial_reports/annual_reports/2018/assets/pdf/pfizer-2018-annual-review.pdf).

---

**Publication**

In mainstream reports

**Status**

Complete

**Attach the document**

Pfizer\_10-K-2019.pdf

**Page/Section reference**

P21

**Content elements**

Risks & opportunities

**Comment**

Pfizer's 2019 10-K is available online at <http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/6b8a74bb-3702-4c0a-a181-70df2b0e5cfb.pdf>

---

**Publication**

In voluntary communications

**Status**

Complete

**Attach the document**

eye-on-nature-little-is.pdf

**Page/Section reference**

P1

**Content elements**

Other, please specify (Promotion of Pfizer's sustainability initiatives)

**Comment**

Found online here: <https://pfizer365.com/post/184284798027/eye-on-nature-little-island>

---

**Publication**

In voluntary communications

**Status**

Complete

**Attach the document**

sustaining-development-.pdf

**Page/Section reference**

P1 and linked video

**Content elements**

Other, please specify (Pfizer commitment to SDGs)

**Comment**

Video referenced in communication may be found at: [https://t.umbl.com/redirect?z=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DeYI9YJ9e\\_I4%26list%3DPLVFghMxXNOFPry1Eqi1gkviKHWxgc\\_Ftu%26index%3D4%26cid%3DPfizer365&t=ZGFiZWRIWQzM2M3ZWwMDY5N2NmZTdhNWFiNjc2YTZkMzQxYjQ5ZixLSGpwZ3pqcw%3D%3D&b=t%3Amkh2J\\_eJ9j94Swo6uPjphw&p=https%3A%2F%2Fpfizer365.com%2Fpost%2F186038270787%2Fsustaining-development-around-the-world&m=1](https://t.umbl.com/redirect?z=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DeYI9YJ9e_I4%26list%3DPLVFghMxXNOFPry1Eqi1gkviKHWxgc_Ftu%26index%3D4%26cid%3DPfizer365&t=ZGFiZWRIWQzM2M3ZWwMDY5N2NmZTdhNWFiNjc2YTZkMzQxYjQ5ZixLSGpwZ3pqcw%3D%3D&b=t%3Amkh2J_eJ9j94Swo6uPjphw&p=https%3A%2F%2Fpfizer365.com%2Fpost%2F186038270787%2Fsustaining-development-around-the-world&m=1)

---

**Publication**

In voluntary communications

**Status**

Complete

**Attach the document**

Pfizer\_Climate\_Change\_Position\_Statement.pdf

**Page/Section reference**

P1

**Content elements**

Strategy

**Comment**

Pfizer's Climate Change Position Statement may be found at:  
[http://www.pfizer.com/files/responsibility/protecting\\_environment/Pfizer\\_Climate\\_Change\\_Position\\_Statement.pdf](http://www.pfizer.com/files/responsibility/protecting_environment/Pfizer_Climate_Change_Position_Statement.pdf)

---

**Publication**

In voluntary communications

**Status**

Complete

**Attach the document**

Climate\_Change\_and\_Human\_Health.pdf

**Page/Section reference**

P1

**Content elements**

Strategy

**Comment**

Document may be found online at  
[https://www.pfizer.com/files/responsibility/protecting\\_environment/Climate\\_Change\\_and\\_Human\\_Health.pdf](https://www.pfizer.com/files/responsibility/protecting_environment/Climate_Change_and_Human_Health.pdf)

---

C14. Signoff

---

C-FI

---

**(C-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.**

C14.1

---

**(C14.1) Provide details for the person that has signed off (approved) your CDP climate change response.**

	Job title	Corresponding job category
Row 1	CFO & EVP, Global Supply and Business Operations	Chief Financial Officer (CFO)

SC. Supply chain module

---

SC0.0

---

(SC0.0) If you would like to do so, please provide a separate introduction to this module.

## SC0.1

---

(SC0.1) What is your company's annual revenue for the stated reporting period?

	Annual Revenue
Row 1	53647000000

## SC0.2

---

(SC0.2) Do you have an ISIN for your company that you would be willing to share with CDP?

Yes

## SC0.2a

---

(SC0.2a) Please use the table below to share your ISIN.

	ISIN country code (2 letters)	ISIN numeric identifier and single check digit (10 numbers overall)
Row 1	US	7170811035

## SC1.1

---

(SC1.1) Allocate your emissions to your customers listed below according to the goods or services you have sold them in this reporting period.

**Requesting member**

CVS Health

**Scope of emissions**

Scope 1

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

1677

**Uncertainty (±%)**

10

**Major sources of emissions**

Fuel used by manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

CVS Health

**Scope of emissions**

Scope 2

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

3906

**Uncertainty (±%)**

10

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

Target Corporation

**Scope of emissions**

Scope 1

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

903

**Uncertainty (±%)**

10

**Major sources of emissions**

Fuel used by manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

Target Corporation

**Scope of emissions**

Scope 2

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO2e**

2103

**Uncertainty (±%)**

10

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

Johnson & Johnson

**Scope of emissions**

Scope 1

**Allocation level**

Facility

**Allocation level detail**

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

**Emissions in metric tonnes of CO2e**

439

**Uncertainty (±%)**

10

**Major sources of emissions**

Fuel used by manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on mass of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Estimate based on manufacturing operations at the Kalamazoo facility only

---

**Requesting member**

Johnson & Johnson

**Scope of emissions**

Scope 2

---

**Allocation level**

Facility

**Allocation level detail**

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

**Emissions in metric tonnes of CO2e**

677

**Uncertainty (±%)**

10

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on mass of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Estimate based on manufacturing operations at the Kalamazoo facility only

---

**Requesting member**

Tesco

**Scope of emissions**

Scope 1

**Allocation level**

Company wide

**Allocation level detail****Emissions in metric tonnes of CO2e**

0

**Uncertainty (±%)**

10

**Major sources of emissions****Verified**

Yes

**Allocation method**

Other, please specify (No data available to support allocation)

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made****Requesting member**

Tesco

**Scope of emissions**

Scope 2

**Allocation level**

Company wide

**Allocation level detail****Emissions in metric tonnes of CO2e**

0

**Uncertainty (±%)**

10

---

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Other, please specify (No data available to support allocation)

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

---

**Requesting member**

Walmart, Inc.

**Scope of emissions**

Scope 1

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

3224

**Uncertainty (±%)**

10

**Major sources of emissions**

Fuel used by manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

Walmart, Inc.

**Scope of emissions**

Scope 2

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

7511

**Uncertainty (±%)**

10

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

---

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available)

---

**Requesting member**

Wal Mart de Mexico

**Scope of emissions**

Scope 1

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

3224

**Uncertainty (±%)**

10

**Major sources of emissions**

Fuel used by manufacturing facilities

**Verified**

Please select

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available). Unable to segregate sales to Wal Mart de Mexico only; figures reported represent allocation to Wal Mart Inc.

---

**Requesting member**

Wal Mart de Mexico

**Scope of emissions**

Scope 2

**Allocation level**

Business unit (subsidiary company)

**Allocation level detail**

Allocation based on manufacturing operations for the Consumer Health business unit

**Emissions in metric tonnes of CO<sub>2</sub>e**

7511

**Uncertainty (±%)**

10

**Major sources of emissions**

Purchased electricity, steam and heat for manufacturing operations

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Allocation based on manufacturing operations only and includes Consumer Healthcare products only (pharma revenue data not available). Unable to segregate sales to Wal Mart de Mexico only; figures reported represent allocation to Wal Mart Inc.

---

**Requesting member**

U.S. General Services Administration - OMB ICR #3090-0319

**Scope of emissions**

Scope 1

**Allocation level**

Company wide

**Allocation level detail****Emissions in metric tonnes of CO2e**

17680

**Uncertainty (±%)**

10

**Major sources of emissions**

Largest contributor to Scope 1 emissions is fuel used by manufacturing operations; data also includes Fleet consumption

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Unable to obtain data to estimate at a business unit or site level; figures above based on Pfizer's corporate footprint.

---

**Requesting member**

U.S. General Services Administration - OMB ICR #3090-0319

**Scope of emissions**

Scope 2

**Allocation level**

Company wide

**Allocation level detail****Emissions in metric tonnes of CO2e**

21483

**Uncertainty (±%)**

10

**Major sources of emissions**

Electricity, steam and heat used by Pfizer's manufacturing operations account for approximately 80% of Pfizer's global Scope 2 emissions.

**Verified**

Yes

**Allocation method**

Allocation based on the market value of products purchased

**Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

Unable to obtain data to estimate at a business unit or site level; figures above based on Pfizer's corporate footprint.

---

**SC1.2**

---

**(SC1.2) Where published information has been used in completing SC1.1, please provide a reference(s).**

The allocations provided in SC 1.1 are based on a revenue percentage (total sales to customer/total revenue). Where possible this calculation is based on the total revenue for a single site or group of sites. Where this information isn't available the calculation is based on the total sales/Pfizer's total revenue as published in annual financial reports.

**SC1.3**

---

**(SC1.3) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?**

Allocation challenges	Please explain what would help you overcome these challenges
Customer base is too large and diverse to accurately track emissions to the customer level	Better coordination/consolidation of customer spend data internally and/or the ability to normalize emissions based on production volume rather than spend

**SC1.4**

---

**(SC1.4) Do you plan to develop your capabilities to allocate emissions to your customers in the future?**

Yes

**SC1.4a**

---

**(SC1.4a) Describe how you plan to develop your capabilities.**

Pfizer continues to explore opportunities to normalize emissions across our diverse manufacturing operations. We are also looking to simplify processes for consolidating spend by customer.

**SC2.1**

---

**(SC2.1) Please propose any mutually beneficial climate-related projects you could collaborate on with specific CDP Supply Chain members.**

**SC2.2**

---

**(SC2.2) Have requests or initiatives by CDP Supply Chain members prompted your organization to take organizational-level emissions reduction initiatives?**

No

**SC3.1**

---

**(SC3.1) Do you want to enroll in the 2019-2020 CDP Action Exchange initiative?**

No

**SC3.2**

---

**(SC3.2) Is your company a participating supplier in CDP's 2018-2019 Action Exchange initiative?**

No

## SC4.1

---

**(SC4.1) Are you providing product level data for your organization's goods or services?**

No, I am not providing data

## Submit your response

---

**In which language are you submitting your response?**

English

**Please confirm how your response should be handled by CDP**

	Public or Non-Public Submission	I am submitting to	Are you ready to submit the additional Supply Chain Questions?
I am submitting my response	Public	Investors Customers	Yes, submit Supply Chain Questions now

**Please confirm below**

I have read and accept the applicable Terms